- Preclinical literature supports anti-inflammatory biological activity.
- FDA reviewed KPV-related bulk substances for wound healing and inflammatory conditions in July 2026.
RESEARCH REBEL • EVIDENCE DOSSIER
KPV
PRECLINICAL • HUMAN EXPOSURE NOT ESTABLISHEDAn α-MSH-derived tripeptide investigated for anti-inflammatory mechanisms. FDA states it has not identified human exposure data for KPV drug products by any route.
- Human efficacy and pharmacokinetics.
- Validated human dosing.
- Route/formulation-specific human safety.
PUBLISHED PROTOCOL EVIDENCE
Study parameter ≠ universal protocol.
No validated human protocol is established. Animal doses and community amounts are not converted into human recommendations.
Numerical study entries carry:PopulationRouteFormulationAmountFrequencyDurationEndpointSource
COMMUNITY EVIDENCE
Document it. Don't upgrade it.
Community oral, topical and injectable reports are recorded separately from controlled evidence.
Reported amount/rangeRouteFrequencyDurationGoalReported positivesReported negativesConcurrent compoundsSource + N
COMMUNITY-REPORTED • NOT CLINICALLY VALIDATED